Samsung Biologics Co., Ltd.

Samsung Biologics is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish as well as laboratory testing support for the biopharmaceutical products we manufacture. In Bio Campus I, our state-of-the-art facilities are cGMP compliant with bioreactors ranging from small to large scales with a total 604KL capacity to serve varying client needs. In response to global biomanufacturing demands, Samsung Biologics announced plans to expand its footprint to Bio Campus II with the construction of Plant 5 with additional 180KL capacity, which will be operational in April 2025. Additionally, Samsung Biologics America enables the company to work in closer proximity to clients based in the U.S. and Europe. We continue to upgrade our capabilities to accommodate our clients by investing in technologies such as an antibody-drug conjugate (ADC) facility, a dedicated mRNA manufacturing facility, and additional aseptic filling capacity. As a sustainable CDMO partner of choice, we are committed to on-time, in-full delivery of the products we manufacture with our flexible manufacturing solutions, operational excellence, and proven expertise.